34 active not recruiting, 12 completed, 9 recruiting, 4 unknown. 47 Phase 2, 15 Phase 1, 2 Not applicable.
Follow Refractory Lymphoma: new trials by email Literature Review of Refractory Lymphoma trials Research Report on Refractory Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL GB5005 CART - Non-hodgkin Lymphoma, Refractory Lymphoma | Phase 1 | Recruiting | The First Affiliated Hospital of Xiamen University | 45 | 2026-04-30 | 2026-03-13 |
| Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma BAFF CAR-T, Obinutuzumab, Cyclophosphamide - Relapsed CLL, Refractory CLL | Phase 1 | Recruiting | Paolo Caimi, MD | 18 | 2025-07-15 | 2025-11-10 |
| Axicabtagene Ciloleucel Injection in Patients With Relapsed/Refractory Follicular Lymphoma Axicabtagene Ciloleucel - Lymphoma, Follicular Lymphoma | Phase 2 | Recruiting | The First Affiliated Hospital of Xiamen University | 30 | 2025-02-08 | 2025-02-13 |
| Epco, Zanu, Ritux for R/R FL or MZL Zanubrutinib, Rituximab, Epcoritamab - Follicular Lymphoma, Lymphoma | Phase 2 | Recruiting | Reid Merryman, MD | 71 | 2025-01-21 | 2026-09-25 |
| A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor HDM2005 - Advanced Solid Tumors, Refractory Lymphoma | Phase 1 | Recruiting | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 111 | 2024-08-12 | 2024-09-26 |
| Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T) Adaptive Bridging Radiation Therapy (ABRT) - Lymphoma, B-Cell, Relapsed Cancer | Not applicable | Completed | Massachusetts General Hospital | 10 | 2024-01-14 | 2026-10-15 |
| Salvage Treatment With Glofitamab in R/R B-NHL: a GIMEMA-FIL Study B-cell Non Hodgkin Lymphoma, Relapse | Completed | Gruppo Italiano Malattie EMatologiche dell'Adulto | 59 | 2023-12-22 | 2026-07-28 | |
| Venetoclax Plus IM2 Regimen for Relapsed and Refractory T Lymphoblastic Lymphoma/Leukemia BCL2 Inhibitor plus IM2 regimen - T-lymphoblastic Lymphoma, Relapsed Disease | Phase 2 | Unknown | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 30 | 2023-01-10 | 2023-06-28 |
| Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M) Biopsy, Biospecimen Collection, Computed Tomography - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2022-02-22 | 2024-05-06 | |
| CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy - Diffuse Midline Glioma, H3 K27-Altered, Metastatic Malignant Neoplasm in the Central Nervous System | Phase 1 / Phase 2 | Recruiting | Children's Oncology Group | 63 | 2022-01-28 | 2026-09-11 |
| Solving Riddles Through Sequencing Next Generation Sequencing - Leukemia, Hematologic Malignancy | Recruiting | Munich Leukemia Laboratory | 100 | 2022-01-19 | 2026-10-09 | |
| Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors Elimusertib - Recurrent Alveolar Rhabdomyosarcoma, Recurrent Ewing Sarcoma | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 31 | 2021-12-22 | 2026-01-23 |
| Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies Ibrutinib Combined With Rituximab - DLBCL, MYD88 Gene Mutation | Phase 2 | Unknown | Chinese Academy of Medical Sciences | 20 | 2021-10-01 | 2021-08-06 |
| Avo In R/R And Previously Untreated MCL Acalabrutinib, Venetoclax, Obinutuzumab - Mantle Cell Lymphoma, Refractory Lymphoma | Phase 1 / Phase 2 | Recruiting | Austin I Kim | 72 | 2021-07-02 | 2026-01-21 |
| Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study Biospecimen Collection, Ipilimumab, Nivolumab - Constitutional Mismatch Repair Deficiency Syndrome, Hematopoietic and Lymphoid Cell Neoplasm | Phase 1 | Withdrawn | National Cancer Institute (NCI) | 2021-05-11 | 2026-06-10 | |
| Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography - Hematopoietic and Lymphatic System Neoplasm, Recurrent Ependymoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 1 | 2021-05-03 | 2026-10-09 |
| Radiation Post-CAR T in Refractory Lymphoma Radiotherapy - Hematologic Malignancy, Refractory Lymphoma | Not applicable | Terminated | Massachusetts General Hospital | 3 | 2021-01-05 | 2025-09-24 |
| Dual Target CAR-T Cells in B-cell Lymphoma dual target CAR-T cell therapy - Lymphoma, B-Cell, Relapse/Recurrence | Phase 1 / Phase 2 | Unknown | YuLi | 20 | 2020-10-20 | 2021-01-26 |
| Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas Entinostat, Molibresib - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 1 | Withdrawn | National Cancer Institute (NCI) | 2020-09-18 | 2020-09-28 | |
| Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Haematological Malignancies Next generation functional drug screening, Comprehensive genomic profiling - Advanced Lymphoma, Refractory Lymphoma | Unknown | Medical University of Vienna | 150 | 2020-06-10 | 2024-03-22 |
Showing 20 of 64. Sign in to see all of them.
Lymphoma (64) · Multiple Myeloma (34) · Hematologic Neoplasms (25) · Recurrence (6) · Lymphoma, Non-Hodgkin (5) · Central Nervous System Neoplasms (4) · Lymphoma, B-Cell (4) · Lymphoma, Large B-Cell, Diffuse (4) · Glioma (3) · Leukemia (3) · Lymphoma, Follicular (3) · Pancreatic Neoplasms (3) · Lymphoma, Mantle-Cell (2) · Lymphoma, T-Cell (2) · Neuroblastoma (2)
Hemic and Lymphatic Diseases (64) · Immune System Diseases (64) · Immunoproliferative Disorders (64) · Lymphatic Diseases (64) · Lymphoproliferative Disorders (64) · Neoplasms (64) · Neoplasms by Histologic Type (64) · Hematologic Diseases (42) · Blood Protein Disorders (34) · Cardiovascular Diseases (34) · Hemorrhagic Disorders (34) · Hemostatic Disorders (34) · Neoplasms, Plasma Cell (34) · Paraproteinemias (34) · Vascular Diseases (34)
Biopsy (19) · Specimen Handling (19) · Magnetic Resonance Spectroscopy (15) · Nuclear Medicine Department, Hospital (6) · X-Rays (6) · Crizotinib (5) · trametinib (5) · Nivolumab (4) · Rituximab (4) · Afatinib (3) · GSK2636771 (3) · copanlisib (3) · palbociclib (3) · sapanisertib (3) · 2-(3-(2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo(f)imidazo(1,2-d)(1,4)oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide (2)
National Cancer Institute (NCI) (41) · Children's Oncology Group (3) · Massachusetts General Hospital (2) · The First Affiliated Hospital of Xiamen University (2) · Austin I Kim (1) · Canadian Cancer Trials Group (1) · Chinese Academy of Medical Sciences (1) · Curis, Inc. (1) · Genta Incorporated (1) · Gruppo Italiano Malattie EMatologiche dell'Adulto (1) · Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (1) · M.D. Anderson Cancer Center (1) · Mayo Clinic (1) · Medical University of Vienna (1) · Munich Leukemia Laboratory (1)
United States (51) · China (5) · Canada (3) · Australia (2) · Puerto Rico (2) · Austria (1) · Germany (1) · Guam (1) · Italy (1) · Taiwan (1)
David S Hong (3) · Filip Janku (3) · Bing Xu (2) · Jason J Luke (2) · John L Hays (2) · Kevin M Kalinsky (2) · Nilofer S Azad (2) · Aaron S Mansfield (1) · Alain C Mita (1) · Alice T Shaw (1) · Amy S Clark (1) · Andrea T Franson (1) · Andrew Bukowinski (1) · Anne S Tsao (1) · Austin I Kim, MD (1)
PMID 32463741, PMID 26586415, PMID 27049457, PMID 28860342, PMID 30393943, PMID 31765263, PMID 33048619, PMID 34766217, PMID 35133871, PMID 35138919, PMID 36351402, PMID 36658425, PMID 37053535, PMID 37322121, PMID 37934000, PMID 38591867, PMID 39352751, PMID 39666929, PMID 39693587, PMID 39913886, PMID 39998852, PMID 40153687, PMID 40178467, PMID 40865033, PMID 41066729, PMID 41533998, PMID 41556942, PMID 42144261, PMID 42308463, PMID 42867148
U10CA180820 (36), U24CA196172 (21), UM1CA097452 (3), UM1CA228823 (2), P30CA015704 (1), P30CA016672 (1), P50CA097274 (1), U10CA180886 (1), UM1CA154967 (1), UM1CA186689 (1)